Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Profiling for Neoadjuvant Therapy in Pancreatic Cancer
NCT01726582Phase 2Completed
- Sponsor
- Medical College of Wisconsin
- Start
- Nov 2011
- Primary completion
- Jun 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, irinotecan, oxaliplatin, gemcitabine, cisplatin and 2 more in pancreatic adenocarcinoma (PDAC), sponsored by Medical College of Wisconsin. Primary endpoint: Number of Subjects Completing Therapy Including Surgical Resection. Started Nov 2011; status: completed.
02
Drugs
fluorouracilirinotecanoxaliplatingemcitabinecisplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01726582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01726582.